Home Neuronal Signaling Adrenergic Receptor agonist Tizanidine HCl

research use only

Tizanidine HCl Adrenergic Receptor agonist

Cat.No.S1437

Tizanidine HCl (DS 103-282) is an α2-adrenergic receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons.
Tizanidine HCl Adrenergic Receptor agonist Chemical Structure

Chemical Structure

Molecular Weight: 290.17

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S143701 Water]15 mg/mL]false]DMSO]10 mg/mL]false]Ethanol]Insoluble]false Purity: 99.87%
99.87

Chemical Information, Storage & Stability

Molecular Weight 290.17 Formula

C9H8ClN5S.HCl

 Storage (From the date of receipt)
CAS No. 64461-82-1 Download SDF Storage of Stock Solutions

Synonyms DS 103-282 Smiles C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl.Cl

Solubility

In vitro
Batch:

Water : 15 mg/mL

DMSO : 10 mg/mL (34.46 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
α2-adrenergic receptor [1]

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01844674 Completed
Malignant Melanoma Neoplasms
Hoffmann-La Roche
 September 2 2013 Phase 1
NCT01839279 Completed
Spasticity
Acorda Therapeutics
 April 2013 Phase 2
NCT01405950 Terminated
Spasticity Due to Cerebral Palsy
Acorda Therapeutics|Syneos Health
 May 2011 Phase 1
NCT01065987 Completed
Healthy
Dr. Reddy''s Laboratories Limited
 September 2001 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map